KEDI U.S. Medical AI Index

NVIDIA's Q2 FY2027 earnings report on August 26, 2026, is expected to have a high price impact (>10%) based on historical volatility and is scheduled.

Q2 2026 earnings release is scheduled.

Natera is expected to announce its Q2 2026 earnings results on or around August 6, 2026, scheduled. High importance is estimated due to typical high volatility (>10%) following earnings reports.

Q2 2026 earnings release and conference call scheduled. High investor focus on the sales momentum of GLP-1 drugs is expected.

Q2 2026 earnings release is scheduled for August 5, 2026, based on past reporting schedules; this is estimated to have a low impact as it is a routine announcement scheduled.

Q2 2026 earnings release is scheduled. Analysts forecast EPS of $-0.24 and revenue of $12.93M. High importance is estimated due to expected price volatility exceeding 10% following the report; scheduled.

AbbVie is scheduled to announce its second-quarter 2026 financial results before the market opens, as announced on June 26, 2026. A Low impact is estimated as the announcement of the date itself typically has minimal immediate price effect, scheduled.

Tempus AI is scheduled to report its second quarter 2026 financial results on July 30, 2026; a >5% price drop following the date announcement suggests significant impact, scheduled.

Second quarter and first half 2026 financial results are scheduled to be released on 2026-07-27. Major earnings reports typically impact stock prices by over 5%, so a significant market reaction is expected.

Analysts forecast EPS around $2.87 and revenue of $113.6 billion for the Q2 2026 earnings release on July 22, 2026, with a focus on continued Cloud growth and AI monetization. This event is estimated to have a ≥5% price impact and is scheduled.

Q2 2026 earnings release is scheduled for 2026-07-16. Analysts forecast EPS around $2.48 on revenue of approximately $2.82 billion. High importance estimated due to typical price volatility following earnings reports, scheduled.

Schrodinger entered into a global drug discovery and development collaboration with Simcere Pharmaceutical on July 10, 2026; this is estimated to have a medium impact due to potential milestone payments.

AstraZeneca announced that the CARDIO-TTRansform Phase III trial for its heart disease drug Wainua (eplontersen), co-developed with Ionis, did not meet its primary endpoint on 2026-07-09, resulting in a 7.7% stock price decline.

Announced that its Signatera personalized molecular residual disease (MRD) test received certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR) on July 9, 2026. Medium importance is estimated based on market expansion potential (>5%).

NVIDIA officially denied rumors of a delay to its Kyber NVL144 AI platform on July 7, 2026, reaffirming that the product roadmap remains on schedule, which led to a stock price increase of over 1%.

The European Commission approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Evercore ISI lowered its price target on Caris Life Sciences to $25 from $30, while maintaining an 'Outperform' rating on July 6, 2026.